Vigilant Biosciences Announces Poster Presentation on Measuring CD44 and Total Protein Levels to Predict Head and Neck Squamous Cell Carcinoma at 7th European Conference on Head and Neck Oncology

Vigilant Biosciences Announces Poster Presentation on Measuring CD44 and Total Protein Levels to Predict Head and Neck Squamous Cell Carcinoma at 7th European Conference on Head and Neck Oncology September 6, 2016 FORT LAUDERDALE, Florida and BUDAPEST, Hungary Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and

© 2020 Vigilant Biosciences

Follow Us

3900001 Rev2